Johnson & Johnson
Ortho Biotech extends a March 1990 agreement with Xoma which covers the development of Xoma's CD5+ and other immunoconjugates for graft v. host disease and organ transplant rejection to include Type I diabetes and other uses except rheumatoid arthritis. On June 10, an FDA advisory panel recommended approval of CD5+ in treating GvHD. The drug is in Phase I for the treatment of Type I diabetes and Phase II for inflammatory bowel disease. Under a 1990 pact, Ortho will market the product under the Orthozyme brandname.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth